Recent discussions on X about Amgen (AMGN) have centered around the stock's price movements and technical indicators. Many users have noted the stock's recent decline, with some highlighting a strong uptrend from June lows and bullish signals in technical charts. There’s also chatter about positive earnings reports and promising updates on drug trials sparking interest among investors.
Additionally, posts on X reflect curiosity about Amgen’s broader market position, with some pointing to increased short interest as a sign of skepticism, while others remain optimistic about long-term growth prospects. The mix of technical analysis and fundamental updates keeps the conversation dynamic. This ongoing buzz illustrates the diverse perspectives on Amgen’s current trajectory in the biotech sector.
Note: This discussion summary was generated from an AI condensation of post data.
Amgen Congressional Stock Trading
Members of Congress have traded $AMGN stock 10 times in the past 6 months. Of those trades, 7 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $AMGN stock by members of Congress over the last 6 months:
- REPRESENTATIVE CLIFF BENTZ purchased up to $15,000 on 06/06.
- REPRESENTATIVE MARJORIE TAYLOR GREENE has traded it 2 times. They made 2 purchases worth up to $30,000 on 05/14, 05/05 and 0 sales.
- REPRESENTATIVE JEFFERSON SHREVE has traded it 3 times. They made 2 purchases worth up to $100,000 on 04/11, 02/24 and 1 sale worth up to $50,000 on 05/12.
- REPRESENTATIVE JARED MOSKOWITZ has traded it 2 times. They made 2 purchases worth up to $30,000 on 04/16 and 0 sales.
- SENATOR TOMMY TUBERVILLE sold up to $50,000 on 04/15.
- REPRESENTATIVE ROBERT BRESNAHAN sold up to $15,000 on 04/08.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Amgen Insider Trading Activity
Amgen insiders have traded $AMGN stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $AMGN stock by insiders over the last 6 months:
- DAVID M REESE (EVP & Chief Technology Officer) has made 0 purchases and 2 sales selling 33,936 shares for an estimated $10,233,747.
- JONATHAN P GRAHAM (EVP & Gen. Counsel & Secy.) sold 25,045 shares for an estimated $7,341,122
- MURDO GORDON (EVP, Global Commercial Ops) sold 8,771 shares for an estimated $2,585,644
- ESTEBAN SANTOS (EVP, Operations) sold 8,711 shares for an estimated $2,550,903
- DEREK MILLER (SVP, Human Resources) has made 0 purchases and 2 sales selling 2,024 shares for an estimated $593,933.
- NANCY A. GRYGIEL (SVP & CCO) sold 1,589 shares for an estimated $483,807
- RACHNA KHOSLA (SVP, Business Development) sold 1,500 shares for an estimated $434,520
- MATTHEW C. BUSCH (VP, Finance & CAO) sold 1,000 shares for an estimated $279,690
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Amgen Hedge Fund Activity
We have seen 1,304 institutional investors add shares of Amgen stock to their portfolio, and 1,322 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS added 10,205,899 shares (+157.1%) to their portfolio in Q1 2025, for an estimated $3,179,647,833
- GAMMA INVESTING LLC removed 3,649,816 shares (-99.7%) from their portfolio in Q2 2025, for an estimated $1,019,065,125
- CAPITAL INTERNATIONAL INVESTORS added 2,922,800 shares (+23.9%) to their portfolio in Q1 2025, for an estimated $910,598,340
- MORGAN STANLEY added 1,674,499 shares (+11.5%) to their portfolio in Q1 2025, for an estimated $521,690,163
- PACER ADVISORS, INC. added 1,489,446 shares (+1686.7%) to their portfolio in Q1 2025, for an estimated $464,036,901
- BOSTON PARTNERS removed 1,458,208 shares (-64.5%) from their portfolio in Q1 2025, for an estimated $454,304,702
- JPMORGAN CHASE & CO added 1,294,292 shares (+51.2%) to their portfolio in Q1 2025, for an estimated $403,236,672
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Amgen Analyst Ratings
Wall Street analysts have issued reports on $AMGN in the last several months. We have seen 3 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 06/27/2025
- RBC Capital issued a "Outperform" rating on 05/02/2025
- B of A Securities issued a "Underperform" rating on 03/05/2025
- BMO Capital issued a "Outperform" rating on 01/29/2025
To track analyst ratings and price targets for Amgen, check out Quiver Quantitative's $AMGN forecast page.
Amgen Price Targets
Multiple analysts have issued price targets for $AMGN recently. We have seen 11 analysts offer price targets for $AMGN in the last 6 months, with a median target of $315.0.
Here are some recent targets:
- David Amsellem from Piper Sandler set a target price of $328.0 on 06/27/2025
- Carter Gould from Cantor Fitzgerald set a target price of $305.0 on 06/24/2025
- Vamil Divan from Guggenheim set a target price of $288.0 on 05/20/2025
- Salim Syed from Mizuho set a target price of $280.0 on 05/07/2025
- Trung Huynh from UBS set a target price of $315.0 on 05/02/2025
- Gregory Renza from RBC Capital set a target price of $320.0 on 05/02/2025
- Terence Flynn from Morgan Stanley set a target price of $330.0 on 04/09/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
